Advertisement

Pathology & Oncology Research

, Volume 23, Issue 4, pp 723–730 | Cite as

Turning back the Wheel: Inducing Mesenchymal to Epithelial Transition via Wilms Tumor 1 Knockdown in Human Mesothelioma Cell Lines to Influence Proliferation, Invasiveness, and Chemotaxis

  • Till Plönes
  • Mitja Fischer
  • Kerstin Höhne
  • Hiromi Sato
  • Joachim Müller-Quernheim
  • Gernot Zissel
Original Article

Abstract

Malignant pleural mesothelioma (MPM) is a highly aggressive tumor that arises from the surface of the pleura and is associated with a history of asbestos exposure. The tumor is characterized by a strong local invasiveness and a poor response to any single modality therapy. Therefore clinical outcome of patients with MPM is poor and median survival time of untreated patients with MPM is 7 months from initial diagnosis. The Wilms Tumor Protein 1 (WT1) is a transcription factor which is highly expressed by MPM and is involved in cellular development and survival. We evaluated the role of WT1 in two human MPM cell lines (MSTO and H2052) expressing high levels of WT1. We performed a knockdown of WT1 using siRNA. Knockdown of WT1 was confirmed by Westernblotting. After knockdown of WT1 we investigated the effect on proliferation, chemoresistance, chemotaxis and migration. We could demonstrate that knockdown of WT1 suppresses chemoresistance in both cell lines compared with control (scrambled siRNA). Additionally, WT1 knockdown reduces proliferation, chemotaxis and invasiveness of mesothelioma cell lines. WT1 reduces malignancy of malignant mesothelioma cell lines and might be a new molecular target in mesothelioma therapy. Further investigations are needed to discover the mechanisms of chemoresistance depending on WT1.

Keywords

Wilms tumor Pleural Asbestos Pleuropneumonectomy Decortication Met Stem cells EPP P/D Epigenetics EMT Epithelial to mesenchymal transition Cancer Chemoresistance Cisplatin Drug 

Notes

Acknowledgement

This work is support by the grant of the Stiftung Mattern (Universitätsklinikum Freiburg).

Supplementary material

12253_2016_181_MOESM1_ESM.docx (13 kb)
Supplemental table 1 (DOCX 12 kb)

References

  1. 1.
    Merritt N, Blewett CJ, Miller JD, Bennett WF, Young JE, Urschel JD (2001) Survival after conservative (palliative) management of pleural malignant mesothelioma. J Surg Oncol 78:171–174CrossRefPubMedGoogle Scholar
  2. 2.
    Ploenes T, Osei-Agyemang T, Nestle U, Waller CF, Passlick B (2012) Malignant pleural mesothelioma. Dtsch Med Wochenschr 137:481–486CrossRefPubMedGoogle Scholar
  3. 3.
    Ceresoli GL, Locati LD, Ferreri AJ, Cozzarini C, Passoni P, Melloni G, Zannini P, Bolognesi A, Villa E (2001) Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. Lung Cancer 34:279–287CrossRefPubMedGoogle Scholar
  4. 4.
    Casarsa C, Bassani N, Ambrogi F, Zabucchi G, Boracchi P, Biganzoli E, Coradini D (2011) Epithelial-to-mesenchymal transition, cell polarity and stemness-associated features in malignant pleural mesothelioma. Cancer Lett 302:136–143CrossRefPubMedGoogle Scholar
  5. 5.
    Peinado H, Olmeda D, Cano A (2007) Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 7:415–428CrossRefPubMedGoogle Scholar
  6. 6.
    Kushitani K, Takeshima Y, Amatya VJ, Furonaka O, Sakatani A, Inai K (2007) Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma. Pathol Int 57:190–199CrossRefPubMedGoogle Scholar
  7. 7.
    von Gise A, Zhou B, Honor LB, Ma Q, Petryk A, Pu WT (2011) WT1 regulates epicardial epithelial to mesenchymal transition through beta-catenin and retinoic acid signaling pathways. Dev Biol 356:421–431CrossRefGoogle Scholar
  8. 8.
    Davies JA, Ladomery M, Hohenstein P, Michael L, Shafe A, Spraggon L, Hastie N (2004) Development of an siRNA-based method for repressing specific genes in renal organ culture and its use to show that the Wt1 tumour suppressor is required for nephron differentiation. Hum Mol Genet 13:235–246CrossRefPubMedGoogle Scholar
  9. 9.
    Chau YY, Hastie ND (2012) The role of Wt1 in regulating mesenchyme in cancer, development, and tissue homeostasis. Trends Genet 28:515–524CrossRefPubMedGoogle Scholar
  10. 10.
    Hohenstein P, Hastie ND (2006) The many facets of the Wilms' tumour gene, WT1. Hum Mol Genet 15(Spec No 2):R196–201Google Scholar
  11. 11.
    Koesters R, Linnebacher M, Coy JF, Germann A, Schwitalle Y, Findeisen P, von Knebel Doeberitz M (2004) WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells. Int J Cancer 109:385–392CrossRefPubMedGoogle Scholar
  12. 12.
    Loeb DM, Evron E, Patel CB, Sharma PM, Niranjan B, Buluwela L, Weitzman SA, Korz D, Sukumar S (2001) Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation. Cancer Res 61:921–925PubMedGoogle Scholar
  13. 13.
    Oji Y, Miyoshi S, Maeda H, Hayashi S, Tamaki H, Nakatsuka S, Yao M, Takahashi E, Nakano Y, Hirabayashi H, Shintani Y, Oka Y, Tsuboi A, Hosen N, Asada M, Fujioka T, Murakami M, Kanato K, Motomura M, Kim EH, Kawakami M, Ikegame K, Ogawa H, Aozasa K, Kawase I, Sugiyama H (2002) Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers. Int J Cancer 100:297–303CrossRefPubMedGoogle Scholar
  14. 14.
    Ploenes T, Osei-Agyemang T, Krohn A, Waller CF, Duncker-Rohr V, Elze M, Passlick B (2013) Changes in lung function after surgery for mesothelioma. Asian Cardiovasc Thorac Ann 21:48–55CrossRefPubMedGoogle Scholar
  15. 15.
    Ploenes T, Scholtes B, Krohn A, Burger M, Passlick B, Muller-Quernheim J, Zissel G (2013) CC-chemokine ligand 18 induces epithelial to mesenchymal transition in lung cancer A549 cells and elevates the invasive potential. PLoS One 8:e53068CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Miller-Hodges E, Hohenstein P (2012) WT1 in disease: shifting the epithelial-mesenchymal balance. J Pathol 226:229–240CrossRefPubMedGoogle Scholar
  17. 17.
    Sugiyama H (2001) Wilms’ tumor Gene WT1: its oncogenic function and clinical application. Int J Hematol 73:177–187CrossRefPubMedGoogle Scholar
  18. 18.
    Zamora-Avila DE, Franco-Molina MA, Trejo-Avila LM, Rodriguez-Padilla C, Resendez-Perez D, Zapata-Benavides P (2007) RNAi silencing of the WT1 gene inhibits cell proliferation and induces apoptosis in the B16F10 murine melanoma cell line. Melanoma Res 17:341–348CrossRefPubMedGoogle Scholar
  19. 19.
    Dohi S, Ohno S, Ohno Y, Soma G, Kyo S, Inoue M (2009) Correlation between WT1 expression and cell proliferation in endometrial cancer. Anticancer Res 29:4887–4891PubMedGoogle Scholar
  20. 20.
    Rong Y, Cheng L, Ning H, Zou J, Zhang Y, Xu F, Liu L, Chang Z, Fu XY (2006) Wilms' tumor 1 and signal transducers and activators of transcription 3 synergistically promote cell proliferation: a possible mechanism in sporadic Wilms' tumor. Cancer Res 66:8049–8057CrossRefPubMedGoogle Scholar
  21. 21.
    Hewitt SM, Hamada S, McDonnell TJ, Rauscher FJ 3rd, Saunders GF (1995) Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1. Cancer Res 55:5386–5389PubMedGoogle Scholar
  22. 22.
    Englert C, Maheswaran S, Garvin AJ, Kreidberg J, Haber DA (1997) Induction of p21 by the Wilms' tumor suppressor gene WT1. Cancer Res 57:1429–1434PubMedGoogle Scholar
  23. 23.
    Mayo MW, Wang CY, Drouin SS, Madrid LV, Marshall AF, Reed JC, Weissman BE, Baldwin AS (1999) WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene. EMBO J 18:3990–4003CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H, Kita K, Hiraoka A, Masaoka T, Nasu K et al (1994) WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 84:3071–3079PubMedGoogle Scholar
  25. 25.
    Bergmann L, Miething C, Maurer U, Brieger J, Karakas T, Weidmann E, Hoelzer D (1997) High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 90:1217–1225PubMedGoogle Scholar
  26. 26.
    Chen MY, Clark AJ, Chan DC, Ware JL, Holt SE, Chidambaram A, Fillmore HL, Broaddus WC (2011) Wilms' tumor 1 silencing decreases the viability and chemoresistance of glioblastoma cells in vitro: a potential role for IGF-1R de-repression. J Neuro-Oncol 103:87–102CrossRefGoogle Scholar
  27. 27.
    Zapata-Benavides P, Manilla-Munoz E, Zamora-Avila DE, Saavedra-Alonso S, Franco-Molina MA, Trejo-Avila LM, Davalos-Aranda G, Rodriguez-Padilla C (2012) WT1 silencing by RNAi synergizes with chemotherapeutic agents and induces chemosensitization to doxorubicin and cisplatin in B16F10 murine melanoma cells. Oncol Lett 3:751–755PubMedPubMedCentralGoogle Scholar
  28. 28.
    Barbolina MV, Adley BP, Shea LD, Stack MS (2008) Wilms tumor gene protein 1 is associated with ovarian cancer metastasis and modulates cell invasion. Cancer 112:1632–1641CrossRefPubMedGoogle Scholar
  29. 29.
    Jomgeow T, Oji Y, Tsuji N, Ikeda Y, Ito K, Tsuda A, Nakazawa T, Tatsumi N, Sakaguchi N, Takashima S, Shirakata T, Nishida S, Hosen N, Kawakami M, Tsuboi A, Oka Y, Itoh K, Sugiyama H (2006) Wilms' tumor gene WT1 17AA(−)/KTS(−) isoform induces morphological changes and promotes cell migration and invasion in vitro. Cancer Sci 97:259–270CrossRefPubMedGoogle Scholar
  30. 30.
    Zhang TF, Yu SQ, Guan LS, Wang ZY (2003) Inhibition of breast cancer cell growth by the Wilms' tumor suppressor WT1 is associated with a destabilization of beta-catenin. Anticancer Res 23:3575–3584PubMedGoogle Scholar
  31. 31.
    Maiti S, Alam R, Amos CI, Huff V (2000) Frequent association of beta-catenin and WT1 mutations in Wilms tumors. Cancer Res 60:6288–6292PubMedGoogle Scholar
  32. 32.
    Kirschner KM, Wagner N, Wagner KD, Wellmann S, Scholz H (2006) The Wilms tumor suppressor Wt1 promotes cell adhesion through transcriptional activation of the alpha4integrin gene. J Biol Chem 281:31930–31939CrossRefPubMedGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2017

Authors and Affiliations

  • Till Plönes
    • 1
    • 2
  • Mitja Fischer
    • 2
  • Kerstin Höhne
    • 2
  • Hiromi Sato
    • 3
  • Joachim Müller-Quernheim
    • 2
  • Gernot Zissel
    • 2
  1. 1.Department of Thoracic Surgery and Thoracic EndoscopyRuhrlandklinik, West German Lung Center, University Hospital Essen, University Duisburg-EssenEssenGermany
  2. 2.Department of Pneumology, Center for MedicineMedical Center University of FreiburgFreiburgGermany
  3. 3.Graduate School of Pharmaceutical Sciences, Department of Clinical Pharmacology & PharmacometricsChiba UniversityChibaJapan

Personalised recommendations